查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600592

细胞治疗市场：按细胞类型、治疗类型、应用和最终用户划分 - 2025-2030 年全球预测

Cell Therapy Market by Cell Type (Differentiated Cell, Stem Cell), Therapy Type (Allogenic Therapies, Autologous Therapies), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞治疗市场2023年估值为86.6亿美元，预计到2024年将达到96亿美元，复合年增长率为10.93%，预计到2030年将达到179.1亿美元。

细胞疗法再生医学的前沿是使用活细胞来修復或替换受损的组织和器官。此治疗方法的应用范围广泛，包括肿瘤学、神经学、骨科、心血管疾病等。需求在于它有可能为传统治疗方法不足的慢性疾病、遗传性疾病和退化性疾病提供解决方案。最终用途部分包括对这些治疗方法的开发、测试和应用至关重要的临床研究机构、医院和专科中心。市场成长要素包括慢性病盛行率的增加、细胞研究的进步以及有利的法律规范。最新的机会在于不断发展的领域，例如个人化医疗（其中 CAR-T 细胞疗法在特定癌症中处于主导）以及干细胞疗法的扩大应用。采用人工智慧和机器学习来改善细胞发育过程也是一个充满希望的前景。然而，复杂的监管环境、高生产成本以及严格政策导致的商业化有限等挑战正在限製成长潜力。由于道德问题和有限的长期疗效资料，市场接受度也存在犹豫。创新应着重于可扩展的製造解决方案、降低成本和先进的临床测试，以确保安全性和有效性。公司还可以探索与学术机构建立合作伙伴关係，以实现研究协同效应。市场是动态的，其特点是技术快速发展，公司必须保持灵活性并遵守不断变化的法规。医疗基础设施和生物技术投资不断增加的新兴市场存在成长机会。此外，投资教育宣传活动以提高公众意识和理解可以提高市场接受度。为了取得成功，相关人员必须利用技术创新和协作创新来克服挑战并推动细胞疗法在全球的采用和成功。

主要市场统计
基准年[2023] 86.6亿美元
预测年份 [2024] 96亿美元
预测年份 [2030] 179.1亿美元
复合年增长率（%） 10.93%

市场动态：揭示快速发展的细胞治疗市场的关键市场洞察

供需的动态交互作用正在改变细胞治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 政府增加对生物技术创新和细胞疗法核准率的投资
    • 改善细胞治疗供应链
  • 市场限制因素
    • 与干细胞移植相关的副作用
  • 市场机会
    • 嵌合体抗原受体 T 细胞 (CAR-T) 疗法以及 ESC（胚胎干细胞）和 iPSC（诱导性多功能干细胞）在癌症治疗中的应用取得进展
    • 增加干细胞在治疗神经系统疾病的应用
  • 市场问题
    • 与干细胞使用相关的伦理和药理学问题

波特五力：驾驭细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞治疗市场的外部影响

外部宏观环境因素在塑造细胞治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解细胞治疗市场的竞争格局

对细胞治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：细胞治疗市场供应商的绩效评估

FPNV定位矩阵是评估细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 政府增加对生物技术创新的投资和细胞疗法的核准率
      • 改善细胞治疗供应链
    • 抑制因素
      • 与干细胞移植相关的副作用
    • 机会
      • 嵌合体抗原受体 T 细胞 (CAR-T) 疗法以及 ESC（胚胎干细胞）和 iPSC（诱导性多功能干细胞）在癌症治疗中的应用取得进展
      • 增加干细胞在治疗神经系统疾病的应用
    • 任务
      • 与使用干细胞相关的伦理和药理学问题
  • 市场区隔分析
    • 细胞类型：干细胞治疗用途的进展
    • 治疗类型：在个人化医疗中越来越多地采用自体细胞疗法
    • 应用：细胞疗法在皮肤科应用的进展
    • 最终使用者：细胞疗法在医院和诊所疾病管理的多种应用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化

第六章细胞治疗市场：依细胞类型

  • 介绍
  • 分化细胞
  • 干细胞

第七章细胞治疗市场：依治疗类型

  • 介绍
  • 同种异体疗法
  • 家庭治疗

第八章细胞治疗市场：依应用分类

  • 介绍
  • 自体免疫疾病
  • 皮肤科
  • 肌肉骨骼治疗
  • 肿瘤学

第九章细胞治疗市场：依最终使用者分类

  • 介绍
  • 生物技术和製药公司
  • 医院和诊所
  • 研究所

第十章美洲细胞治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太细胞治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲细胞治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Pluri推出新的细胞疗法 CDMO 部门
    • Max Healthcare 推出 CAR-T 细胞疗法，以改善新德里的癌症治疗
    • 拜耳开设第一家细胞疗法製造工厂，推动全球再生医学发展

公司名单

  • Athersys, Inc.
  • Sartorius AG
  • BioNTech SE
  • Anterogen Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Novartis AG
  • Thermo Fisher Scientific, Inc.
  • Stempeutics Research Pvt. Ltd.
  • Vericel Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Mesoblast Ltd.
  • Castle Creek Biosciences, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Medipost Co., Ltd.
  • Smith & Nephew PLC
  • Bone Therapeutics SA
  • NuVasive, Inc.
  • Kolon TissueGene, Inc.
  • Lonza Group Ltd.
  • Astellas Pharma Inc.
  • TegoScience
  • Bristol-Myers Squibb Company
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market was valued at USD 8.66 billion in 2023, expected to reach USD 9.60 billion in 2024, and is projected to grow at a CAGR of 10.93%, to USD 17.91 billion by 2030.

Cell therapy, a cutting-edge frontier in regenerative medicine, involves the administration of living cells to repair or replace damaged tissues and organs. The scope of this therapy spans applications in oncology, neurology, orthopedics, and cardiovascular conditions among others. Its necessity is driven by its potential to provide solutions for chronic diseases, genetic disorders, and degenerative conditions where traditional treatments fall short. End-use sectors include clinical research organizations, hospitals, and specialized cell therapy centers, all crucial for developing, testing, and applying these therapies. Market growth factors include increasing prevalence of chronic diseases, advancements in cell-based research, and favorable regulatory frameworks. The latest opportunities lie in evolving areas like personalized medicine, with CAR-T cell therapy leading the charge against specific cancers, and expanding applications in stem cell therapy. Adoption of AI and machine learning in improving cell development processes is another promising prospect. However, challenges such as complex regulatory landscapes, high production costs, and limited commercialization due to stringent policies restrain growth potential. There is also hesitancy in market acceptance stemming from ethical concerns and limited long-term efficacy data. Innovations should focus on scalable manufacturing solutions, reducing costs, and ensuring safety and efficacy through advanced clinical trials. Companies could explore partnerships with academic institutions for research synergies. The market is dynamic, marked by rapid technological evolution, necessitating players to remain agile and compliant with changing regulations. Opportunities for growth are present in developing markets where healthcare infrastructure advancements and investments in biotech are on the rise. Additionally, investing in educational campaigns to improve public perception and understanding could boost market acceptance. To succeed, stakeholders must navigate the challenges while leveraging technological and collaborative innovations to drive the adoption and success of cell therapies worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 8.66 billion
Estimated Year [2024] USD 9.60 billion
Forecast Year [2030] USD 17.91 billion
CAGR (%) 10.93%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Therapy Market

The Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
    • Improvements in Cell Therapy Supply Chain
  • Market Restraints
    • Side Effects Related to the Stem Cell Transplant
  • Market Opportunities
    • Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
    • Increasing Use of Stem Cells for the Treatment of Neurological disorders
  • Market Challenges
    • Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues

Porter's Five Forces: A Strategic Tool for Navigating the Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Therapy Market

A detailed market share analysis in the Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Athersys, Inc., Sartorius AG, BioNTech SE, Anterogen Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis AG, Thermo Fisher Scientific, Inc., Stempeutics Research Pvt. Ltd., Vericel Corporation, JCR Pharmaceuticals Co., Ltd., Mesoblast Ltd., Castle Creek Biosciences, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Stemedica Cell Technologies, Inc., Medipost Co., Ltd., Smith & Nephew PLC, Bone Therapeutics SA, NuVasive, Inc., Kolon TissueGene, Inc., Lonza Group Ltd., Astellas Pharma Inc., TegoScience, and Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cell Type, market is studied across Differentiated Cell and Stem Cell.
  • Based on Therapy Type, market is studied across Allogenic Therapies and Autologous Therapies.
  • Based on Application, market is studied across Autoimmune Diseases, Dermatology, Musculoskeletal Therapies, and Oncology.
  • Based on End-User, market is studied across Biotechnology and Pharmaceutical Companies, Hospitals and Clinics, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Government Investment in Biotech Innovation and Approval Rates in Cell Therapy
      • 5.1.1.2. Improvements in Cell Therapy Supply Chain
    • 5.1.2. Restraints
      • 5.1.2.1. Side Effects Related to the Stem Cell Transplant
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Chimeric Antigen Receptor T-cell (CAR-T) Therapies for Cancer Treatments and the Use of ESCs (Embryonic stem cells) and iPSCs (Induced Pluripotent Stem Cells)
      • 5.1.3.2. Increasing Use of Stem Cells for the Treatment of Neurological disorders
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical Issues Associated with the Use of Stem Cells and Pharmacological Issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cell Type: Advancements in stem cells for therapeutic applications
    • 5.2.2. Therapy Type: Increasing adoption of autologous cell therapies for personalized medicines
    • 5.2.3. Application: Advancements in dermatological applications of cell therapies
    • 5.2.4. End-User: Diverse applications of cell therapies in hospitals and clinics for disease management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Cell Therapy Market, by Cell Type

  • 6.1. Introduction
  • 6.2. Differentiated Cell
  • 6.3. Stem Cell

7. Cell Therapy Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Allogenic Therapies
  • 7.3. Autologous Therapies

8. Cell Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Dermatology
  • 8.4. Musculoskeletal Therapies
  • 8.5. Oncology

9. Cell Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Biotechnology and Pharmaceutical Companies
  • 9.3. Hospitals and Clinics
  • 9.4. Research Institutes

10. Americas Cell Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pluri Launches New Cell Therapy CDMO Division
    • 13.3.2. Max Healthcare Launches CAR-T Cell Therapy to Improve Cancer Care in Delhi-NCR
    • 13.3.3. Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale

Companies Mentioned

  • 1. Athersys, Inc.
  • 2. Sartorius AG
  • 3. BioNTech SE
  • 4. Anterogen Co., Ltd.
  • 5. Takeda Pharmaceutical Company Limited
  • 6. Pfizer Inc.
  • 7. Novartis AG
  • 8. Thermo Fisher Scientific, Inc.
  • 9. Stempeutics Research Pvt. Ltd.
  • 10. Vericel Corporation
  • 11. JCR Pharmaceuticals Co., Ltd.
  • 12. Mesoblast Ltd.
  • 13. Castle Creek Biosciences, Inc.
  • 14. FUJIFILM Holdings Corporation
  • 15. Gilead Sciences, Inc.
  • 16. Stemedica Cell Technologies, Inc.
  • 17. Medipost Co., Ltd.
  • 18. Smith & Nephew PLC
  • 19. Bone Therapeutics SA
  • 20. NuVasive, Inc.
  • 21. Kolon TissueGene, Inc.
  • 22. Lonza Group Ltd.
  • 23. Astellas Pharma Inc.
  • 24. TegoScience
  • 25. Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELL THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY DIFFERENTIATED CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023